

## Learner Notification

### MED Learning Group

Seeing The Future: Next-Generation Treatment Approach for DR, AMD, and RVO

June 6, 2023 – June 6, 2024

Online

### Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

### Objectives - After Attending This Program You Should Be Able To

1. Determine the rationale for the use of next-generation therapies such as gene therapy, biosimilars, advanced delivery systems, artificial intelligence, and pharmacological treatments targeting new molecular pathways for the management of patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion.
2. Assess the safety, efficacy, and mechanisms and rationale for next-generation therapies for diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion.
3. Evaluate recent clinical data of next-generation therapeutic strategies for DR, AMD or RVO.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Ana Maria	Albino	NA
Daniel	DaSilva	NA
Diana V.	Do	Apellis, Iveric Bio, Kodiak Sciences, Genentech, Regeneron, Kriya, Boehringer Ingelheim: Consultant, Regeneron, Kriya, Boehringer Ingelheim: Contracted Research, Kodiak Sciences: Stock Shareholder
Jessica	Feygin	NA
Matthew	Frese	NA
Christina	Gallo	NA
Nicole	Longo	NA
Chimene	Richa	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)